Reproducibility of Novel Immune-Inflammatory Biomarkers Over 4 Months: An Analysis with Repeated Measures Design

References

• Campisi G , ChiappelliM, DeMartinis Met al. Pathophysiology of age-related diseases. Immun. Ageing6(1), 12 (2009).
   PubMedGoogle Scholar
• Campisi J , RobertL. Cell senescence: role in aging and age-related diseases. Interdiscip. Top Gerontol.39, 45–61 (2014).
   PubMedGoogle Scholar
• Gianesin K , Noguera-JulianA, ZanchettaMet al. Premature aging and immune senescence in HIV-infected children. AIDS30(9), 1363–1373 (2016).
   PubMed Web of Science ®Google Scholar
• Howcroft TK , CampisiJ, LouisGBet al. The role of inflammation in age-related disease. Aging5(1), 84–93 (2013).
   PubMedGoogle Scholar
• Franceschi C , CampisiJ. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci.69(Suppl 1), S4–S9 (2014).
   PubMed Web of Science ®Google Scholar
• Gallo V , EggerM, McCormackVet al. STrengthening the Reporting of OBservational studies in Epidemiology: Molecular Epidemiology STROBE-ME. An extension of the STROBE statement. J. Epidemiol. Community Health66(9), 844–854 (2012).
   PubMed Web of Science ®Google Scholar
• Beaufort N , LeducD, RousselleJCet al. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol.172(1), 540–549 (2004).
   PubMed Web of Science ®Google Scholar
• Falgarone G , ChiocchiaG. Clusterin: a multifacet protein at the crossroad of inflammation and autoimmunity. Adv. Cancer Res.104, 139–170 (2009).
   PubMed Web of Science ®Google Scholar
• Hall BE , WankhadeUD, KonkelJEet al. Transforming growth factor-beta3 (TGF-beta3) knock-in ameliorates inflammation due to TGF-beta1 deficiency while promoting glucose tolerance. J. Biol. Che.m288(44), 32074–32092 (2013).
   PubMed Web of Science ®Google Scholar
• Mitchell RA , LiaoH, ChesneyJet al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl Acad. Sci. USA99(1), 345–350 (2002).
   PubMed Web of Science ®Google Scholar
• Lenferink AE , CantinC, NantelAet al. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene29(6), 831–844 (2010).
   PubMed Web of Science ®Google Scholar
• Li MO , WanYY, SanjabiS, RobertsonAK, FlavellRA. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol.24, 99–146 (2006).
   PubMed Web of Science ®Google Scholar
• Lund LR , RomerJ, RonneE, EllisV, BlasiF, DanoK. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J.10(11), 3399–3407 (1991).
   PubMed Web of Science ®Google Scholar
• Boeing H , WahrendorfJ, BeckerN. EPIC-Germany – a source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann. Nutr. Metab.43(4), 195–204 (1999).
   PubMedGoogle Scholar
• di Giuseppe R , HircheF, MontonenJet al. Reliability of plasma fibroblast growth factor 23 as risk biomarker in epidemiological studies measured over a four-month period. Ann. Clin. Biochem.49(Pt 6), 542–545 (2012).
   PubMedGoogle Scholar
• Eichelmann F , RudovichN, PfeifferAFet al. Novel adipokines: methodological utility in human obesity research. Int. J. Obes.41(6), 976–981 (2017).
   Web of Science ®Google Scholar
• Eichelmann F , WeikertC, di GiuseppeRet al. Methodological utility of chemerin as a novel biomarker of immunity and metabolism. Endocr. Connect.6(5), 340–347 (2017).
   PubMed Web of Science ®Google Scholar
• InterAct Consortium , PetersT, BrageSet al. Validity of a short questionnaire to assess physical activity in 10 European countries. Eur. J. Epidemiol.27(1), 15–25 (2012).
   Web of Science ®Google Scholar
• Cardemil F . Comparison analysis and applications of the Bland–Altman method: correlation or agreement?Medwave17(1), e6852 (2017).
   Google Scholar
• Shannon P , MarkielA, OzierOet al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res.13(11), 2498–2504 (2003).
   PubMed Web of Science ®Google Scholar
• Wendt MK , TianM, SchiemannWP. Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res.347(1), 85–101 (2012).
   PubMed Web of Science ®Google Scholar
• Thuno M , MachoB, Eugen-OlsenJ. suPAR: the molecular crystal ball. Dis. Markers27(3), 157–172 (2009).
   PubMed Web of Science ®Google Scholar
• Backes Y , vander Sluijs KF, MackieDPet al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med.38(9), 1418–1428 (2012).
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J , AndersenO, LinnebergAet al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J. Intern. Med.268(3), 296–308 (2010).
   PubMed Web of Science ®Google Scholar
• Lv L , WangF, WuLet al. Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. Nephrol. Dial. Transplant. (2018).[Epub ahead of print]
   Web of Science ®Google Scholar
• Persson M , OstlingG, SmithGet al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke45(1), 18–23 (2014).
   PubMed Web of Science ®Google Scholar
• Schumacher M , WannerC, BeyersmannJ. Soluble urokinase receptor and chronic kidney disease. N. Engl. J. Med.374(9), 890 (2016).
   Google Scholar
• Taniguchi Y , ShimamuraY, HorinoT, FujimotoS, TeradaY. Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease. Kidney Int.86(1), 209–210 (2014).
   Web of Science ®Google Scholar
• Haupt TH , RasmussenLJH, KallemoseTet al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun. Ageing16(1), 1 (2019).
   PubMed Web of Science ®Google Scholar
• Degoma EM , FrenchB, DunbarRL, AllisonMA, MohlerER3rd, BudoffMJ. Intraindividual variability of C-reactive protein: the multi-ethnic study of atherosclerosis. Atherosclerosis224(1), 274–279 (2012).
   Web of Science ®Google Scholar
• Lyngbaek S , SehestedtT, MarottJLet al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int. J. Cardiol.167(3), 781–785 (2013).
   PubMed Web of Science ®Google Scholar
• Grima J , PineauC, BardinCW, ChengCY. Rat Sertoli cell clusterin, alpha 2-macroglobulin, and testins: biosynthesis and differential regulation by germ cells. Mol. Cell. Endocrinol.89(1–2), 127–140 (1992).
   Web of Science ®Google Scholar
• Kujiraoka T , HattoriH, MiwaYet al. Serum apolipoprotein J in health, coronary heart disease and Type 2 diabetes mellitus. J. Atheroscler. Thromb.13(6), 314–322 (2006).
   Web of Science ®Google Scholar
• Schrijvers EM , KoudstaalPJ, HofmanA, BretelerMM. Plasma clusterin and the risk of Alzheimer disease. JAMA305(13), 1322–1326 (2011).
   PubMed Web of Science ®Google Scholar
• Bertuzzi M , MarelliC, BagnatiRet al. Plasma clusterin as a candidate pre-diagnosis marker of colorectal cancer risk in the Florence cohort of the European Prospective Investigation into Cancer and Nutrition: a pilot study. BMC Cancer15, 56 (2015).
   Web of Science ®Google Scholar
• Xue YM , DengCY, WeiWet al. Macrophage migration inhibitory factor promotes cardiac fibroblast proliferation through the Src kinase signaling pathway. Mol. Med. Rep.17(2), 3425–3431 (2018).
   Web of Science ®Google Scholar
• Calandra T , BernhagenJ, MetzCNet al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature377(6544), 68–71 (1995).
   PubMed Web of Science ®Google Scholar
• Morrison MC , KleemannR. Role of macrophage migration inhibitory factor in obesity, insulin resistance, Type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. Front Immunol.6, 308 (2015).
   PubMed Web of Science ®Google Scholar
• Kassaar O , PereiraMorais M, XuSet al. Macrophage migration inhibitory factor is subjected to glucose modification and oxidation in Alzheimer's disease. Sci. Rep.7, 42874 (2017).
   Web of Science ®Google Scholar
• Zhao YM , WangL, DaiZet al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int. J. Cancer129(10), 2463–2472 (2011).
   Web of Science ®Google Scholar